Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Pfizer, Novo Nordisk Intensify Fight For Metsera As Buyout Offers Continue To Climb

Business,Mergers,And,Acquisitions,Concept.,Share,Acquisition,,Asset,Business,Acquisition,

Adding more drama to Metsera Inc.’s (NASDAQ:MTSR) acquisition deal, Novo Nordisk A/S (NYSE:NVO) increased the deal proposal to $62.20 per share in cash, up from $56.50.

• Watch the MTSR momentum here.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.